Delving Into Site-Specific Conjugations to Create Homogenous ADCs
Time: 1:01 pm
day: Pre-Conference Workshop Day
Details:
In the last two years, the proportion of clinically site-specific ADC has increased from 23% to 29%*, and novel site-specific conjugation technologies have overtaken traditional cysteine-based site-specific ADCs.
This has given food for thought to ADC developers on what conjugation strategies to employ. It has also made assessing the advantages of site-specific conjugation versus stochastic conjugation, and evaluating different site-specific technologies against themselves a core decision on ADC design.
Attending this workshop will enable you to:
• Discuss the advantages of site-specific conjugation against stochastic conjugation
• Evaluate the different types of site-specific conjugation and which combinations of payload, linker, antibody and target are most amenable to each type
• Analyze conjugation chemistries and examine fundamental process and manufacturing challenges
* According to Beacon Targeted Therapies Data
